Thread by @JACCJournals

#JACCCardioOnc #Tweetorial: Along the spectrum of cancer Tx, #YeSCCT has a lot to offer regarding identifying subclinical #ASCVD, excluding obstructive #cvCAD in cardiotoxicity when appropriate. #CardioOnc, as a field, can gain from incorporating CCT in practice.

🧵1/

#YeSCCT may identify subclinical #ASCVD in cancer patients & survivors. Reviewing previous non-gated thoracic CT scans for CAC may help identify subclinical #cvCAD and start prompt preventive Tx.

#JACCCardioOnc #CardioOnc #MedTwitter #CardioTwitter

2/

Several clinical scenarios in the context of cardiotoxicity may require ruling out obstructive #cvCAD. Cancer pts tend to have ⬆️ risk of complications from invasive procedures➡️ thrombocytopenia & hypercoagulable states. #YeSCCT may derive significant benefit. #JACCCardioOnc

3/

Although #whyCMR has an established role in the assessment of cardiac masses, when not feasible #YeSCCT may be performed. This figure shows a pt case w/ #melanoma having episodes of VT. CCT was performed to assess for coronary anomaly or obstructive #cvCAD. #JACCCardioOnc

4/

Thank you to the authors of this cardiac computed tomography study @BudoffMD, @onco_cardiology, @datsunian, @sdent_duke, @CardioOnc_MR_CT, @CardiacCTGuy.

Check out the article in #JACCCardioOnc: bit.ly/32eJYfK

#CardioOnc #CardioTwitter #YeSCCT #cvCAD #ASCVD

5/